A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-? maintenance therapy or observation, in small cell lung carcinoma patients with complete responses

Abstract

This study did not show a wide difference in activity and toxicity between CAV-E and CAV-T. The number of patients who entered the second randomization was too small to reach the second study endpoint.

Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer

“…The two most commonly used control regimens were etoposide-cisplatin (EP) and CAV. All but five trials [19][20][21][22][23] compared another chemotherapy regimen with one of these two regimens. In addition, most of the experimental treatment arms were regimens that were variations of one of these two therapies.…”

“…Five trials compared two non-standard chemotherapy regimens, neither of which was CAV nor EP [ [19][20][21][22][23]. These trials included the following regimens: cyclophosphamide with either vincristine or vindesine [19]; etoposide and vindesine with or without cisplatin [20]; doxorubicin-ifosfamidevincristine alternating with etoposide and either cisplatin or carboplatin [21]; doxorubicin and etoposide combined with either cyclophosphamide or cisplatin [22]; and CAVE compared with CAV plus teniposide [23].…”

“…These trials included the following regimens: cyclophosphamide with either vincristine or vindesine [19]; etoposide and vindesine with or without cisplatin [20]; doxorubicin-ifosfamidevincristine alternating with etoposide and either cisplatin or carboplatin [21]; doxorubicin and etoposide combined with either cyclophosphamide or cisplatin [22]; and CAVE compared with CAV plus teniposide [23]. In no trial was an improved survival detected for any regimen, and no trial used concurrent radiation.…”

“…In no trial was an improved survival detected for any regimen, and no trial used concurrent radiation. One trial detected no difference in outcome when comparing the use of standard doses of CAV, given with either etoposide or teniposide [23], suggesting that in the treatment of SCLC, either epidophyllotoxin is acceptable for use in combination chemotherapy.…”

Methodological Challenges in Constructing Effective Treatment Sequences for Chronic Psychiatric Disorders

“…SMART designs are not confirmatory experiments and may not involve a control condition (Dawson and Lavori, 2004). Several studies have implemented variations on the SMART design (Stone et al, 1995;Tummarello et al, 1997;Stroup et al, 2003;Fava et al, 2003;Rush et al, 2004;Rabinowitz et al, 2005).…”